Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. The company markets ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs. Its licensed products include canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States; AT-003, a bupivacaine liposome injectable suspension for post-operative pain in cats; AT-002, a specific formulation of capromorelin for use in cats and dogs; AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis in dogs; AT-006, an anti-viral eprociclovir that is used for the treatment of feline herpes virus-induced ophthalmic conditions in cats; AT-017, a listeria based antigen delivery system for treating canine lymphoma in dogs; AT-019, an EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation, and other indications; and AT-008, a therapeutic candidate for treating canine lymphoma in dogs in Europe. In addition, the company develops other therapeutics for dogs and cats in Europe. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products; and AskAt Inc for the development and commercialization of compound AT-019. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PETX
CUSIPN/A
Phone913-353-1000
Debt
Debt-to-Equity Ratio0.09
Current Ratio3.02
Quick Ratio2.44
Price-To-Earnings
Trailing P/E Ratio-5.53
Forward P/E Ratio-11.17
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.57 million
Price / Sales9.99
Cash FlowN/A
Price / CashN/A
Book Value$1.86 per share
Price / Book2.88
Profitability
EPS (Most Recent Fiscal Year)($0.97)
Net Income$-47,510,000.00
Net Margins-154.23%
Return on Equity-35.25%
Return on Assets-23.57%
Miscellaneous
Employees85
Outstanding Shares47,670,000
Market Cap$257.42 million
Aratana Therapeutics (NASDAQ:PETX) Frequently Asked Questions
What is Aratana Therapeutics' stock symbol?
Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."
How were Aratana Therapeutics' earnings last quarter?
Aratana Therapeutics Inc (NASDAQ:PETX) posted its earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. The biopharmaceutical company earned $4.91 million during the quarter, compared to analysts' expectations of $4.72 million. Aratana Therapeutics had a negative net margin of 154.23% and a negative return on equity of 35.25%. View Aratana Therapeutics' Earnings History.
When is Aratana Therapeutics' next earnings date?
What price target have analysts set for PETX?
5 analysts have issued 1 year target prices for Aratana Therapeutics' stock. Their predictions range from $7.00 to $10.00. On average, they anticipate Aratana Therapeutics' share price to reach $8.40 in the next twelve months. This suggests a possible upside of 56.7% from the stock's current price. View Analyst Price Targets for Aratana Therapeutics.
What is the consensus analysts' recommendation for Aratana Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aratana Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aratana Therapeutics.
Who are some of Aratana Therapeutics' key competitors?
Some companies that are related to Aratana Therapeutics include Deciphera Pharmaceuticals (DCPH), Retrophin (RTRX), Intra-Cellular Therapies (ITCI), Rhythm Pharmaceuticals (RYTM), Zai Lab (ZLAB), Lexicon Pharmaceuticals (LXRX), Athenex (ATNX), Revance Therapeutics (RVNC), Eagle Pharmaceuticals (EGRX), Radius Health (RDUS), Aptinyx (APTX), Akorn (AKRX), Viking Therapeutics (VKTX), Alder Biopharmaceuticals (ALDR) and Amphastar Pharmaceuticals (AMPH).
Who are Aratana Therapeutics' key executives?
Aratana Therapeutics' management team includes the folowing people:
- Dr. Steven St. Peter, Co-Founder, Pres, CEO & Director (Age 52)
- Mr. Craig A. Tooman, CFO & Treasurer (Age 52)
- Mr. Brent A. Standridge, Chief Operating Officer (Age 60)
- Mr. John Paolucci, Director of Marketing
- Dr. Ernst Heinen, Chief Devel. Officer (Age 55)
Who are Aratana Therapeutics' major shareholders?
Aratana Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.11%). Company insiders that own Aratana Therapeutics stock include Brent Standridge, Craig A Tooman, Ernst Heinen, Healthcare Master Fun Broadfin and Peter Steven St. View Institutional Ownership Trends for Aratana Therapeutics.
Which major investors are buying Aratana Therapeutics stock?
How do I buy shares of Aratana Therapeutics?
Shares of PETX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aratana Therapeutics' stock price today?
One share of PETX stock can currently be purchased for approximately $5.36.
How big of a company is Aratana Therapeutics?
Aratana Therapeutics has a market capitalization of $257.42 million and generates $25.57 million in revenue each year. The biopharmaceutical company earns $-47,510,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Aratana Therapeutics employs 85 workers across the globe.
What is Aratana Therapeutics' official website?
How can I contact Aratana Therapeutics?
Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected]
MarketBeat Community Rating for Aratana Therapeutics (NASDAQ PETX)
MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote "Outperform" if you believe PETX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PETX will underperform the S&P 500 over the long term. You may vote once every thirty days.
